<DOC>
	<DOCNO>NCT01265498</DOCNO>
	<brief_summary>Administration farnesoid X receptor ( FXR ) ligand obeticholic acid ( OCA ) 72 week subject biopsy evidence nonalcoholic steatohepatitis ( NASH ) result improvement liver disease measure change nonalcoholic fatty liver disease ( NAFLD ) activity score ( NAS ) .</brief_summary>
	<brief_title>The Farnesoid X Receptor ( FXR ) Ligand Obeticholic Acid NASH Treatment Trial ( FLINT )</brief_title>
	<detailed_description>To evaluate whether treatment obeticholic acid , 25 mg daily 72 week compare treatment placebo , improve severity nonalcoholic fatty liver disease ( NAFLD ) determine hepatic histology .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>18 year age older initial screen interview provision consent Histologic evidence definite probable nonalcoholic steatohepatitis ( NASH ) base upon liver biopsy obtain 90 day prior randomization nonalcoholic fatty liver disease activity score ( NAS ) 4 great least 1 component NAS score ( steatosis score 03 , balloon degeneration score 02 , lobular inflammation score 03 ) . Current history significant alcohol consumption period 3 consecutive month within 1 year prior screening ( significant alcohol consumption define 20 gram per day females 30 gram per day male , average ) Inability reliably quantify alcohol consumption base upon local study physician judgment Use drug historically associate nonalcoholic fatty liver disease ( NAFLD ) ( amiodarone , methotrexate , systemic glucocorticoid , tetracycline , tamoxifen , estrogens dos great use hormone replacement , anabolic steroid , valproic acid , know hepatotoxin ) 2 week year prior randomization Prior plan ( study period ) bariatric surgery ( eg , gastroplasty , rouxenY gastric bypass ) Uncontrolled diabetes define Hemoglobin A1c 9.5 % high within 60 day prior enrollment Presence cirrhosis liver biopsy A platelet count 100,000/mm3 Clinical evidence hepatic decompensation define presence follow abnormality : Serum albumin less 3.2 grams/deciliter ( g/dL ) International Normalized Ratio ( INR ) great 1.3 Direct bilirubin great 1.3 milligram per deciliter ( mg/dL ) History esophageal varix , ascites hepatic encephalopathy Evidence form chronic liver disease : Hepatitis B define presence hepatitis B surface antigen ( HBsAg ) Hepatitis C define presence hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) positive hepatitis C antibody ( antiHCV ) Evidence ongoing autoimmune liver disease define compatible liver histology Primary biliary cirrhosis define presence least 2 criterion ( ) Biochemical evidence cholestasis base mainly alkaline phosphatase elevation ( ii ) Presence antimitochondrial antibody ( AMA ) ( iii ) Histologic evidence nonsuppurative destructive cholangitis destruction interlobular bile duct Primary sclerosing cholangitis Wilson 's disease define ceruloplasmin limit normal compatible liver histology Alpha1antitrypsin ( A1AT ) deficiency define diagnostic feature liver histology ( confirm alpha1 antitrypsin level less normal ; exclusion discretion study physician ) History hemochromatosis iron overload define presence 3+ 4+ stainable iron liver biopsy Druginduced liver disease define basis typical exposure history Known bile duct obstruction Suspected proven liver cancer Any type liver disease nonalcoholic steatohepatitis ( NASH ) Serum alanine aminotransferase ( ALT ) great 300 unit per liter ( U/L ) Serum creatinine 2.0 mg/dL great Use ursodeoxycholic acid ( Ursodiol , Urso ) within 90 day prior enrollment Inability safely obtain liver biopsy History biliary diversion Known positivity Human Immunodeficiency Virus ( HIV ) infection Active , serious medical disease likely life expectancy le 5 year Active substance abuse include inhale injection drug year prior screening Pregnancy , plan pregnancy , potential pregnancy unwillingness use effective birth control trial , breast feeding Participation investigational new drug ( IND ) trial 30 day randomization Any condition , opinion investigator , would impede compliance hinder completion study Failure give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Farnesoid X Receptor</keyword>
	<keyword>FXR</keyword>
	<keyword>Nonalcoholic fatty liver disease</keyword>
	<keyword>Nonalcoholic steatohepatitis</keyword>
	<keyword>NAFLD</keyword>
	<keyword>NASH</keyword>
	<keyword>obeticholic acid</keyword>
</DOC>